Key Points
- Director Phillip Md Et Al Frost purchased 20,000 shares on Nov. 25 at an average price of $0.94 ($18,800), increasing his stake to 1,699,551 shares — a reported 1.19% ownership rise valued at approximately $1.598M.
- Shares trade around $0.94 with a $12.98M market cap; the company reported quarterly EPS of -$0.19 (beat estimates by $0.03) but analysts forecast -1.85 EPS for the year, and ratings are mixed with Weiss Ratings reiterating a "sell (e+)" while the consensus is a "Hold" with an average target of $6.00.
Cocrystal Pharma, Inc. (NASDAQ:COCP - Get Free Report) Director Phillip Md Et Al Frost purchased 20,000 shares of the business's stock in a transaction that occurred on Tuesday, November 25th. The stock was acquired at an average price of $0.94 per share, with a total value of $18,800.00. Following the purchase, the director owned 1,699,551 shares in the company, valued at $1,597,577.94. This represents a 1.19% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Cocrystal Pharma Trading Down 1.8%
Shares of COCP opened at $0.94 on Wednesday. The firm has a market cap of $12.98 million, a P/E ratio of -1.00 and a beta of 2.24. Cocrystal Pharma, Inc. has a 12 month low of $0.90 and a 12 month high of $3.26. The stock's 50 day moving average is $1.12 and its two-hundred day moving average is $1.41.
Cocrystal Pharma (NASDAQ:COCP - Get Free Report) last announced its earnings results on Friday, November 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.03. Equities research analysts forecast that Cocrystal Pharma, Inc. will post -1.85 EPS for the current year.
Analysts Set New Price Targets
Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of Cocrystal Pharma in a research report on Tuesday, November 18th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Cocrystal Pharma presently has an average rating of "Hold" and an average target price of $6.00.
Get Our Latest Research Report on Cocrystal Pharma
Cocrystal Pharma Company Profile
(
Get Free Report)
Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
